SCHEDULE: LoPriore Group Boosts Hepion Stake to 26.2%

Vincent LoPriore, Gravitas Capital LP, and Invictus Capital Advisors Pension Plan collectively increased their beneficial ownership of Hepion Pharmaceuticals, Inc. common stock to 26.2%.

Summary

• Vincent LoPriore, Gravitas Capital LP, and Invictus Capital Advisors Pension Plan have jointly filed an amendment to Schedule 13D, increasing their collective beneficial ownership of Hepion Pharmaceuticals, Inc. common stock.
• The reporting persons now beneficially own 26,250,000 shares, representing 26.2% of the outstanding common stock.
• This ownership includes 10,000,000 shares issuable upon exercise of warrants.
• The total purchase price for these shares and warrants was approximately $750,000.
• The shares were acquired for investment purposes, with the possibility of future acquisitions.
• Vincent LoPriore is the Executive Chairman of Hepion Pharmaceuticals, Inc.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, indicating increased investment and potential strategic alignment without immediate negative indicators.

Positives

• Significant increase in beneficial ownership by key individuals and entities associated with management, indicating strong conviction in the company's prospects.
• Acquisition of shares and warrants totaling 26,250,000, demonstrating substantial investment.
• The reporting persons have acquired these securities for investment purposes, suggesting a long-term outlook.
• The total investment of $750,000 for these shares and warrants shows a considerable financial commitment.

Negatives

• The filing does not detail any negative financial performance or operational issues.
• The increase in stake could be interpreted as a precursor to a control change, which may or may not be beneficial depending on future actions.

Risks

• The reporting persons may make further acquisitions of common stock, potentially leading to increased ownership concentration and influence.
• The warrants are immediately exercisable at $0.06 per share, subject to a Beneficial Ownership Limitation, which could lead to further dilution if exercised and not managed carefully.

Future Outlook

The reporting persons state that they may make further acquisitions of the Common Stock from time to time. No other specific future plans or proposals are disclosed.

Management Comments

• Vincent LoPriore is the Executive Chairman of the Issuer.
• Vincent LoPriore is the Managing Member of Gravitas Capital LP.
• Vincent LoPriore is the trustee and beneficiary of the Invictus Capital Advisors Pension Plan.
• Each Reporting Person disclaims beneficial ownership of all securities reported in this Statement except to the extent of such Reporting Persons pecuniary interests therein, other than those securities reported herein as being held directly by such Reporting Persons.

Industry Context

StockSavvy.ai notes that significant stake building by management or affiliated entities in a biopharmaceutical company often signals confidence in the company's pipeline or strategic direction, especially in a sector prone to volatility and requiring substantial capital for development.

Stakeholder Impact

• Shareholders may view the increased stake by management as a positive signal of confidence, potentially supporting share price.
• Other investors may be influenced by this increased ownership, potentially leading to further market activity.
• The concentration of ownership could impact future corporate governance decisions and strategic direction.

Next Steps

• The reporting persons may make further acquisitions of Hepion Pharmaceuticals, Inc. common stock.

Key Dates

Recommendation

The filing indicates increased investment by management-affiliated entities, suggesting confidence. However, it is an ownership disclosure and not a financial performance report. Without further operational or financial data, a 'hold' recommendation is prudent, allowing for observation of how this increased stake influences future company strategy and performance.

Keywords

Hepion Pharmaceuticals, Schedule 13D, Beneficial Ownership, Gravitas Capital LP, Invictus Capital Advisors Pension Plan, Vincent LoPriore, Warrants, Investment